Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
While some say this strategy's failure rate is "too high," it's one step closer to the "white grail" of a shorter 24-week formula.
Read Full NewsThird molar removal may improve oral health markers, but its benefits must be weighed against surgical risks, postoperative morbidity, and cost.
Stopping aspirin early in dual antiplatelet therapy is tied to a lower risk for bleeding with no increase in ischemic risks after coronary stenting, a new meta-analysis finds.
The World Health Organization on Thursday declared the hantavirus outbreak linked to a cruise ship over after the last identified contact of an exposed person completed...
New South Wales became Australia's third state to confirm a case of H5N1 bird flu after authorities said a migratory seabird found near a coastal town returned a positive...
The $500 million seed fund will support universal antiviral platforms and air cleaning technologies.
New study finds nearly 10% of internal medicine residents report a disability; the American Medical Association updates maternity care billing codes; and Texas joins autism trial network.
A phase 3 trial compares first-line fixed-duration venetoclax-obinutuzumab to fludarabine, cyclophosphamide, and rituximab/bendamustine-rituximab in patients with CLL.
1.
For the first time in humans, a chemotherapy drug reaches the brain.
2.
enhancing survivors of brain tumors' quality of life.
3.
In breast-conserving surgery, is micro-CT a useful tool for determining tumor margins?
4.
Fighting for others: How guilt and obligation drive desire for more intensive treatments in end-of-life cancer care
5.
Muscular strength and good physical fitness linked to lower risk of death in people with cancer
1.
Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders
2.
Unveiling the Secrets of Early Cancer: Emerging Strategies to Decipher Its Biology
3.
Advancing Cancer Treatment: Precision Pharmaceutical Care in Oncohematology
4.
Amivantamab Plus Chemotherapy Outperforms Standard Care in Post-Osimertinib NSCLC
5.
Unraveling the Mysteries of Burkitt Lymphoma: A New Hope for Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
2.
Navigating the Complexities of Ph Negative ALL - Part I
3.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge